BR9915946B1 - formulaÇço de vacina para a administraÇço nasal compreendendo antÍgeno de superfÍcie do vÍrus da hepatite b (hbsag) e antÍgeno de nucleocapsÍdeo viral. - Google Patents

formulaÇço de vacina para a administraÇço nasal compreendendo antÍgeno de superfÍcie do vÍrus da hepatite b (hbsag) e antÍgeno de nucleocapsÍdeo viral.

Info

Publication number
BR9915946B1
BR9915946B1 BRPI9915946-5A BR9915946A BR9915946B1 BR 9915946 B1 BR9915946 B1 BR 9915946B1 BR 9915946 A BR9915946 A BR 9915946A BR 9915946 B1 BR9915946 B1 BR 9915946B1
Authority
BR
Brazil
Prior art keywords
antigen
hbsag
hepatitis
nasal administration
vaccine formulation
Prior art date
Application number
BRPI9915946-5A
Other languages
English (en)
Other versions
BR9915946A (pt
Inventor
Julio Cesar Aguilar Rubido
Daniel Octavio Palenzuela Gardon
Verena Lucila Muzio Gonzalez
Gerardo Henrique Guillen Nieto
Eduardo Penton Arias
Dagmara Pichardo Diaz
Henrique Iglesias Perez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR9915946A publication Critical patent/BR9915946A/pt
Publication of BR9915946B1 publication Critical patent/BR9915946B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI9915946-5A 1998-12-02 1999-12-01 formulaÇço de vacina para a administraÇço nasal compreendendo antÍgeno de superfÍcie do vÍrus da hepatite b (hbsag) e antÍgeno de nucleocapsÍdeo viral. BR9915946B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU1998183A CU22871A1 (es) 1998-12-02 1998-12-02 Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
PCT/CU1999/000006 WO2000032229A1 (es) 1998-12-02 1999-12-01 Formulaciones conteniendo particulas semejantes a virus como inmunopotenciadores por via mucosal

Publications (2)

Publication Number Publication Date
BR9915946A BR9915946A (pt) 2001-08-21
BR9915946B1 true BR9915946B1 (pt) 2010-12-14

Family

ID=5459504

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9915946-5A BR9915946B1 (pt) 1998-12-02 1999-12-01 formulaÇço de vacina para a administraÇço nasal compreendendo antÍgeno de superfÍcie do vÍrus da hepatite b (hbsag) e antÍgeno de nucleocapsÍdeo viral.

Country Status (13)

Country Link
US (1) US7374766B1 (pt)
EP (1) EP1136077B1 (pt)
CN (1) CN1191853C (pt)
AR (1) AR021414A1 (pt)
AT (1) ATE331528T1 (pt)
BR (1) BR9915946B1 (pt)
CA (1) CA2352777C (pt)
CU (1) CU22871A1 (pt)
DE (1) DE69932182T2 (pt)
ES (1) ES2264273T3 (pt)
HK (1) HK1042424B (pt)
PT (1) PT1136077E (pt)
WO (1) WO2000032229A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0031079D0 (en) * 2000-12-20 2001-01-31 Smithkline Beecham Plc Vaccine
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
AU2003277448A1 (en) * 2002-10-17 2004-05-04 Enzo Therapeutics, Inc. Transmucosal administration of aggregated antigens
CU23405A1 (es) * 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas para uso terapéutico
EP1764369A1 (de) 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
EP3344293A4 (en) * 2015-09-04 2019-01-16 Inventprise, LLC. STABILIZED VACCINE COMPOSITIONS OF VLP
KR20200038339A (ko) 2015-09-10 2020-04-10 인벤트프라이즈 엘엘씨 다가 vlp 접합체
ES2965709T3 (es) 2016-03-31 2024-04-16 Ct Ingenieria Genetica Biotecnologia Composición farmacéutica que incluye los antígenos de superficie y nucleocápside del virus de la hepatitis B
TWI634899B (zh) * 2016-11-22 2018-09-11 國立臺灣大學 包含類ｂ肝病毒顆粒作為佐劑的疫苗組成物
EP3804752A4 (en) * 2018-06-05 2022-03-09 Toko Yakuhin Kogyo Co., Ltd. TRANSNASAL DELIVERY SYSTEM FOR HEPATITIS B VACCINE
CN111450245A (zh) * 2020-04-29 2020-07-28 艾棣维欣(苏州)生物制药有限公司 一种乙型肝炎治疗疫苗及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547368A (en) * 1983-12-20 1985-10-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hepatitis B core antigen vaccine made by recombinant DNA
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US6319501B1 (en) * 1990-07-19 2001-11-20 Health Research, Inc. Method of immunizing against hepatitis B virus
US5840303A (en) 1991-08-26 1998-11-24 The Scripps Research Foundation Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
HUT68510A (en) 1991-08-26 1995-06-28 Cytel Corp Process for producing hla-restricted hapatitis b virus ctl epitopes and pharmaceutical compositions containing them
EP0642355B1 (en) * 1992-05-23 1998-07-15 SMITHKLINE BEECHAM BIOLOGICALS s.a. Combined vaccines comprising hepatitis b surface antigen and other antigens
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
WO1994012617A1 (en) * 1992-11-25 1994-06-09 International Biotechnology Laboratories, Inc. Hepatitis b virus vaccines
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
FR2732605B1 (fr) 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
RU2189254C2 (ru) * 1995-06-06 2002-09-20 Америкэн Хоум Продактс Корпорэйшн Вакцины против вирусов гепатита
US6153392A (en) 1997-07-30 2000-11-28 Bionova Corporation Devices and methods comprising an HBcAg from hepatitis B virus
ATE333501T1 (de) 1997-09-05 2006-08-15 Medimmune Inc Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus- ähnlichen tielchen (vlps)
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties

Also Published As

Publication number Publication date
CN1191853C (zh) 2005-03-09
ATE331528T1 (de) 2006-07-15
HK1042424B (zh) 2007-05-11
DE69932182D1 (de) 2006-08-10
EP1136077B1 (en) 2006-06-28
BR9915946A (pt) 2001-08-21
EP1136077A1 (en) 2001-09-26
CA2352777C (en) 2009-09-08
HK1042424A1 (en) 2002-08-16
ES2264273T3 (es) 2006-12-16
DE69932182T2 (de) 2007-05-10
US7374766B1 (en) 2008-05-20
WO2000032229A1 (es) 2000-06-08
CN1332637A (zh) 2002-01-23
PT1136077E (pt) 2006-10-31
AR021414A1 (es) 2002-07-17
CU22871A1 (es) 2003-10-21
CA2352777A1 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
BR9915946B1 (pt) formulaÇço de vacina para a administraÇço nasal compreendendo antÍgeno de superfÍcie do vÍrus da hepatite b (hbsag) e antÍgeno de nucleocapsÍdeo viral.
GC0000202A (en) Combined vaccine composition comprising a hepatitis b viral (hbv) antigen and a human papillomavirus(hpv) antigen
NL300365I1 (nl) Recombinante influenzavirussen voor vaccins en gentherapie
EP0595436A3 (en) Swine virus, pathogen of the multiplying respiratory disease, vaccines and its viral DNA.
GB9912254D0 (en) Viral replication detection using a counter virus
ATE376825T1 (de) Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
ATE275631T1 (de) Rekombinanter venezolanische-equine- pferdeenzephalitis-virusimpstoff
EE05442B1 (et) V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks
FI963717A (fi) Uusia mutatoituja viruksia, viruksenvastaisia yhdisteitä ja uusia menetelmiä rokotteiden valmistamiseksi
GC0000201A (en) Combined vaccine composition comprising a herpes simplex virus (hsv) antigen and a human papillomavirus (hpv) antigen
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
LU91327I2 (fr) Vaccin papillomavirus humain Ätypes 56,11,16,18Ü(recombinant, adsorbé)
MX9603896A (es) Vacuna para la prevencion de enfermedades respiratorias y reproductivas del cerdo, que contiene virus parainfluenza.
DE60040727D1 (de) Menschliche papillomavirus impfstoff-formulierungen
PL360096A1 (en) Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
DE69839169D1 (de) Aus infektiöser cDNA gewonnene rekombinate YF Viren-Impfstoffe
NZ288254A (en) Method, including an ultracentrifugation step, for preparing an influenza virus, antigens obtained and applications thereof
FR2728794B1 (fr) Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
AU4932601A (en) Recombinant parainfluenza virus expression systems and vaccines
DZ1706A1 (fr) Vaccin contre le virus de l'hepatite a.
AU2001246331A1 (en) Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof
DE4192786T1 (de) Masernvirus-Rekombinanter Pockenvirus-Impfstoff
IL147605A0 (en) Mosaic infectious bursal disease virus vaccines
EP1749885B8 (en) Infectious and attenuated bovine viral diarrhea virus vaccine
IL131212A0 (en) Recombinant virus and live-virus vaccines

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/12/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.